中国医药导报
中國醫藥導報
중국의약도보
CHINA MEDICAL HERALD
2015年
3期
15-18
,共4页
乳腺癌%乳腺肿瘤%SIRT1%SPARC
乳腺癌%乳腺腫瘤%SIRT1%SPARC
유선암%유선종류%SIRT1%SPARC
Breast cancer,Breast neoplasms%SIRT1%SPARC
目的：探讨沉默信息调节因子(SIRT1)和富含半胱氨酸的酸性分泌蛋白(SPARC)在乳腺癌组织中的表达及其与临床病理指标之间的关系。方法收集潍坊市人民医院2014年1~6月经病理明确诊断的乳腺浸润性导管癌石蜡标本60例和乳腺纤维瘤标本15例,应用免疫组化法检测乳腺癌组织和乳腺纤维腺瘤组织中SIRT1和SPARC的表达情况。结果 SIRT1在乳腺癌组织中的阳性表达率(61.7%,37/60)明显高于乳腺纤维腺瘤组织(33.3%,5/15),差异有统计学意义(P<0.05)；有乳腺癌淋巴结转移的SIRT1高表达率(72.0%,18/25)高于无淋巴结转移(25.7%,9/35),TNM分期为芋期的乳腺癌中SIRT1高表达率(77.3%,17/22)高于玉、域期(26.3%,10/38),差异均有高度统计学意义(P<0.01)。 SPARC在乳腺癌间质细胞的高表达率(73.3%,44/60)明显高于肿瘤细胞(10.0%,6/60)和乳腺纤维腺瘤间质细胞(40.0%,6/15),差异均有统计学意义(P<0.05)；SPARC在乳腺癌有淋巴结转移的高表达率(96.0%,24/25)高于无淋巴结转移的(74.3%,26/35),差异有统计学意义(P<0.05)。结论乳腺癌中SIRT1、SPARC的高表达与乳腺癌的发生、发展、侵袭和转移有关。
目的：探討沉默信息調節因子(SIRT1)和富含半胱氨痠的痠性分泌蛋白(SPARC)在乳腺癌組織中的錶達及其與臨床病理指標之間的關繫。方法收集濰坊市人民醫院2014年1~6月經病理明確診斷的乳腺浸潤性導管癌石蠟標本60例和乳腺纖維瘤標本15例,應用免疫組化法檢測乳腺癌組織和乳腺纖維腺瘤組織中SIRT1和SPARC的錶達情況。結果 SIRT1在乳腺癌組織中的暘性錶達率(61.7%,37/60)明顯高于乳腺纖維腺瘤組織(33.3%,5/15),差異有統計學意義(P<0.05)；有乳腺癌淋巴結轉移的SIRT1高錶達率(72.0%,18/25)高于無淋巴結轉移(25.7%,9/35),TNM分期為芋期的乳腺癌中SIRT1高錶達率(77.3%,17/22)高于玉、域期(26.3%,10/38),差異均有高度統計學意義(P<0.01)。 SPARC在乳腺癌間質細胞的高錶達率(73.3%,44/60)明顯高于腫瘤細胞(10.0%,6/60)和乳腺纖維腺瘤間質細胞(40.0%,6/15),差異均有統計學意義(P<0.05)；SPARC在乳腺癌有淋巴結轉移的高錶達率(96.0%,24/25)高于無淋巴結轉移的(74.3%,26/35),差異有統計學意義(P<0.05)。結論乳腺癌中SIRT1、SPARC的高錶達與乳腺癌的髮生、髮展、侵襲和轉移有關。
목적：탐토침묵신식조절인자(SIRT1)화부함반광안산적산성분비단백(SPARC)재유선암조직중적표체급기여림상병리지표지간적관계。방법수집유방시인민의원2014년1~6월경병리명학진단적유선침윤성도관암석사표본60례화유선섬유류표본15례,응용면역조화법검측유선암조직화유선섬유선류조직중SIRT1화SPARC적표체정황。결과 SIRT1재유선암조직중적양성표체솔(61.7%,37/60)명현고우유선섬유선류조직(33.3%,5/15),차이유통계학의의(P<0.05)；유유선암림파결전이적SIRT1고표체솔(72.0%,18/25)고우무림파결전이(25.7%,9/35),TNM분기위우기적유선암중SIRT1고표체솔(77.3%,17/22)고우옥、역기(26.3%,10/38),차이균유고도통계학의의(P<0.01)。 SPARC재유선암간질세포적고표체솔(73.3%,44/60)명현고우종류세포(10.0%,6/60)화유선섬유선류간질세포(40.0%,6/15),차이균유통계학의의(P<0.05)；SPARC재유선암유림파결전이적고표체솔(96.0%,24/25)고우무림파결전이적(74.3%,26/35),차이유통계학의의(P<0.05)。결론유선암중SIRT1、SPARC적고표체여유선암적발생、발전、침습화전이유관。
Objective To explore the expressions and role of SIRT and SPARC in invasive ductal carcinoma of the breast. Methods 60 samples of pathologically diagnosed breast invasive ductal carcinoma and 15 samples of bresat fi-broadenomastromal tissues in Weifang People's Hospital from January to June 2014 were selected, the expressions of SIRT1 and SPARC in these samples were detected by immunohistochemical technique. Results SIRT1 positive expres-sion rate in breast cancer cells (61.7%, 37/60) was significantly higher than that in breast fibroadenoma (33.3%, 5/15), the difference was statistically significant (P< 0.05); SIRT1 higher expression rate in invasive ductal carcinoma with lymph node metastasis (72.0%, 18/25) was higher than that without lymph node metastasis (25.7%, 9/35), the SIRT1 higher expression rate in TNM Ⅲ (77.3%, 17/22) was significantly higher than that in TNM Ⅰ, II(26.3%, 10/38), the differences were statistically significant (P< 0.01). SPARC higher erexpression rate in breast cancer interstitial cells (73.3%, 44/60) was significantly higher than those in breast cancer tumor cells (10.0%, 6/60) and bresat fibroadenomas-tromal interstitial cells (40.0%, 6/15), the differences were statistically significant (P<0.05). SPARC higher expression rate in breast cancer with lymph node metastasis (96.0%,24/25) was higher that that without lymph node metastasis (74.3%, 26/35). Conclusion The higher expression of SIRT1 and SPARC in breast cancer are involved in breast cancer occurrence, development and prognosis.
